Bayer Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Bayer şirketinin toplam hissedar öz sermayesi €30.7B ve toplam borcu €41.2B olup, bu da borç-öz sermaye oranını 134.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €106.9B ve €76.3B dir. Bayer 'in FAVÖK'ü €9.2B faiz karşılama oranı 11.3 dur. Şirketin €6.3B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

134.1%

Borç/özkaynak oranı

€41.16b

Borç

Faiz karşılama oranı	11.3x
Nakit	€6.34b
Eşitlik	€30.69b
Toplam yükümlülükler	€76.25b
Toplam varlıklar	€106.95b

Son finansal sağlık güncellemeleri

Recent updates

Benign Growth For Bayer Aktiengesellschaft (ETR:BAYN) Underpins Stock's 25% Plummet

Nov 21

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

Sep 13

Bayer Aktiengesellschaft Just Missed Earnings; Here's What Analysts Are Forecasting Now

Aug 09

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

Jun 11

The Market Doesn't Like What It Sees From Bayer Aktiengesellschaft's (ETR:BAYN) Revenues Yet

May 07

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt In A Risky Way

Jan 18

Are Investors Undervaluing Bayer Aktiengesellschaft (ETR:BAYN) By 42%?

Dec 27

Bayer (ETR:BAYN) Takes On Some Risk With Its Use Of Debt

Oct 15

Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Be 45% Below Their Intrinsic Value Estimate

Aug 05

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BAYN 'nin kısa vadeli varlıkları ( €33.1B ) kısa vadeli yükümlülüklerini ( €25.0B ) aşıyor.

Uzun Vadeli Yükümlülükler: BAYN 'un kısa vadeli varlıkları ( €33.1B ) uzun vadeli yükümlülüklerini ( €51.2B ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BAYN 'nin net borç/öz sermaye oranı ( 113.5% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: BAYN şirketinin borç/öz sermaye oranı son 5 yılda 92.1% seviyesinden 134.1% seviyesine yükseldi.

Borç Kapsamı: BAYN 'nin borcu işletme nakit akışı ( 19.4% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: BAYN 'in borcuna ilişkin faiz ödemeleri EBIT ( 11.3 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Bayer Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt In A Risky Way

Bayer (ETR:BAYN) Takes On Some Risk With Its Use Of Debt

Recent updates

Benign Growth For Bayer Aktiengesellschaft (ETR:BAYN) Underpins Stock's 25% Plummet

Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF =40% at AHA 2024

Price target decreased by 7.8% to €32.06

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Bayer and Liveo Research Launches Blister Packaging with Improved Environmental Footprint

Bayer Submits Application for Third Indication of Darolutamide in the EU

U.S. Food and Drug Administration Accepts New Drug Application for Bayer's Elinzanetant

Bayer Ag and BlueRock Therapeutics LP Announces Positive 24-Month Data from exPDite

Bayer Submits Application to U.S. FDA for Third Indication of darolutamide

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer Announces Late-Breaking KERENDIA® (finerenone) Investigational Data Presented

Bayer to Present Phase III Kerendia (Finerenone) Data

Bayer Aktiengesellschaft Just Missed Earnings; Here's What Analysts Are Forecasting Now

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively

Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting

Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

The Market Doesn't Like What It Sees From Bayer Aktiengesellschaft's (ETR:BAYN) Revenues Yet

Upcoming dividend of €0.11 per share

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Price target decreased by 7.7% to €42.48

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Dividend of €0.11 announced

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Bayer Aktiengesellschaft to Report Q1, 2024 Results on May 14, 2024

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt In A Risky Way

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Are Investors Undervaluing Bayer Aktiengesellschaft (ETR:BAYN) By 42%?

Williams Hart & Boundas Wins Against Bayer

Price target decreased by 7.7% to €51.57

Price target decreased by 7.6% to €57.57

Bayer Announces OCEANIC-AF Study Starts Early Due to Lack of Efficacy

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer Provides Update on Aliqopa (Copanlisib)

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 13%

Bayer Announces Pharmacodynamic Data on Kerendia

Bayer Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Bayer (ETR:BAYN) Takes On Some Risk With Its Use Of Debt

Bayer to Present Latest Real-World Evidence of Menopausal Symptoms and Their Treatment

Bayer Aktiengesellschaft (XTRA:BAYN) signed an agreement to acquire strawberry pipeline and commercial portfolio from NIAB.

Bayer AG and BlueRock Therapeutics LP Announces Details of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (BRT-DA01), A Stem Cell Derived Investigational Therapy for Treating Parkinson's Disease

Bayer AG and Bluerock Therapeutics LP Announces Results of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (Brt-Da01)

Bayer AG Announces Management Changes

Consensus EPS estimates fall by 11%

New minor risk - Profit margin trend

Second quarter 2023 earnings released: €1.92 loss per share (vs €0.30 loss in 2Q 2022)

Consensus EPS estimates fall by 12%

Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Be 45% Below Their Intrinsic Value Estimate

Consensus EPS estimates fall by 24%

Bayer Aktiengesellschaft Provides Earnings Guidance for Full-Year 2023

Industrias Químicas del Valles S.A. reached an agreement to acquire Bayer's phytosanitary products factory in Valencia from Bayer Aktiengesellschaft (XTRA:BAYN).

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin